CD79a: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
: | :A pan B-cell marker with relatively high specificity for the identification of B-lineage. CD79a is expressed initially in cytoplasm of early B cells, before appearing on the membrane at the time heavy chains of immunoglobulin become expressed. | ||
| Line 14: | Line 14: | ||
<span style="color:navy">'''Normal expression and function'''</span> | <span style="color:navy">'''Normal expression and function'''</span> | ||
CD79a associates with CD79b and the immunoglobulin chains form part of the B-cell receptor (BCR). CD79a and CD79b each mediate intracellular signalling. However the two chains are expressed slightly differently in B cells - CD79a is a more lineage-specific marker than CD79b and expression is acquired at a very early stage of B-lymphocyte formation. CD79a is expressed initially in cytoplasm before appearing on the membrane of mature cells, persisting until plasma cell differentiation when it is progressively lost. | |||
Revision as of 09:19, 18 May 2023
- Summary
- A pan B-cell marker with relatively high specificity for the identification of B-lineage. CD79a is expressed initially in cytoplasm of early B cells, before appearing on the membrane at the time heavy chains of immunoglobulin become expressed.
Normal expression and function
CD79a associates with CD79b and the immunoglobulin chains form part of the B-cell receptor (BCR). CD79a and CD79b each mediate intracellular signalling. However the two chains are expressed slightly differently in B cells - CD79a is a more lineage-specific marker than CD79b and expression is acquired at a very early stage of B-lymphocyte formation. CD79a is expressed initially in cytoplasm before appearing on the membrane of mature cells, persisting until plasma cell differentiation when it is progressively lost.
Diagnostic role
- xxxxx
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
| Expression in primitive cell types | |||||||
|---|---|---|---|---|---|---|---|
| AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature B cell neoplasms | |||||||
|---|---|---|---|---|---|---|---|
| CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
| Expression in mature T cell neoplasms* | ||||||
|---|---|---|---|---|---|---|
| ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
| ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ||
Notes: xxxxx